公开(公告)号：US11912714B2

公开(公告)日：2024-02-27

申请号：US17983501

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Wei Li ,  Xuri Gao ,  Jiajun Zhang ,  Xiaowen Peng ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230331734A1

公开(公告)日：2023-10-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230295175A1

公开(公告)日：2023-09-21

申请号：US18122892

申请日：2023-03-17

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Xin Zhang ,  Xiaowen Peng ,  Ruichao Shen ,  Jiajun Zhang ,  Wei Li ,  Hui Cao ,  Xuri Gao ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention relates to processes for preparing a compound of Formula (A):




or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.

公开(公告)号：US11339170B1

公开(公告)日：2022-05-24

申请号：US17479455

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri Gao ,  Wei Li ,  Jiajun Zhang ,  Xiaowen Peng ,  Hui Cao ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10442788B2

公开(公告)日：2019-10-15

申请号：US15088517

申请日：2016-04-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Wei Li ,  Jorden Kass ,  Xuri Gao ,  Xiaowen Peng ,  Meizhong Jin ,  Yat Sun Or

IPC: C07D233/64 ,  C07D401/12 ,  C07F7/18 ,  A61K31/4164 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07F9/6558 ,  A61K31/4178 ,  A61K31/661

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190177320A1

公开(公告)日：2019-06-13

申请号：US16210472

申请日：2018-12-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Hui Cao ,  Byung-Chul Suh ,  Yat Sun Or

IPC: C07D471/10 ,  A61P31/14 ,  C07D471/04 ,  C07D471/20

CPC classification number: C07D471/10 ,  A61K45/06 ,  A61P31/14 ,  C07D471/04 ,  C07D471/20

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190119288A1

公开(公告)日：2019-04-25

申请号：US16220267

申请日：2018-12-14

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Xuri Gao ,  Meizhong Jin ,  Yat Sun Or

IPC: C07D487/04 ,  A61P31/20 ,  A61K31/519

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20170253609A1

公开(公告)日：2017-09-07

申请号：US15450125

申请日：2017-03-06

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  A61K31/357 ,  C07C317/32 ,  A61K31/167 ,  A61K31/223 ,  C07C323/42 ,  C07C235/56 ,  C07D313/04 ,  A61K31/335 ,  C07D213/52 ,  A61K31/4402 ,  C07D213/89 ,  A61K31/4425 ,  A61K31/4409 ,  C07D213/81 ,  A61K31/44 ,  C07C311/53 ,  A61K31/18 ,  C07D211/54 ,  A61K31/445 ,  C07D309/08 ,  A61K31/351 ,  C07D303/34 ,  A61K31/336 ,  C07D493/04 ,  C07D401/04 ,  A61K31/4545 ,  C07D307/33 ,  A61K31/365 ,  C07D307/32 ,  A61K31/341 ,  A61K31/196 ,  A61K31/325 ,  A61K31/655 ,  A61K31/215 ,  C07B59/00 ,  C07D261/20 ,  A61K31/416 ,  C07D261/02 ,  A61K31/415 ,  C07D261/08 ,  C07D451/04 ,  A61K31/439 ,  C07D231/12 ,  C07D263/52 ,  A61K31/421 ,  C07D327/10 ,  A61K31/39 ,  C07D207/16 ,  A61K31/401 ,  C07D257/04 ,  A61K31/41 ,  C07D233/64 ,  A61K31/4164 ,  A61K31/277 ,  C07D277/26 ,  A61K31/426 ,  C07D295/088 ,  A61K31/5377 ,  C07D303/26 ,  C07D317/72

CPC classification number: C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/001 ,  C07B2200/05 ,  C07B2200/07 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C317/44 ,  C07C323/42 ,  C07C323/62 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/44 ,  C07C2602/46 ,  C07C2603/74 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US09603895B2

公开(公告)日：2017-03-28

申请号：US14843119

申请日：2015-09-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  Xuri Gao

IPC: A61K38/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  C07K7/52 ,  A61K45/06 ,  C07K7/64

CPC classification number: A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  C07K7/52 ,  C07K7/645 ,  Y02A50/463

Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

公开(公告)号：US20160289212A1

公开(公告)日：2016-10-06

申请号：US15088517

申请日：2016-04-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Wei Li ,  Jorden Kass ,  Xuri Gao ,  Xiaowen Peng ,  Meizhong Jin ,  Yat Sun Or

IPC: C07D401/12 ,  A61K31/695 ,  A61K45/06 ,  A61K31/454 ,  C07D409/14 ,  C07D403/12 ,  A61K31/55 ,  C07D233/64 ,  A61K31/4164 ,  C07D413/12 ,  A61K31/5377 ,  A61K31/496 ,  C07D417/14 ,  C07D413/14 ,  C07D401/14 ,  A61K31/553 ,  C07F7/18

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R1  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 其抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的HBV生命周期的功能，并且也可用作抗病毒剂。 本发明还涉及包含用于给患有HBV感染的受试者的上述化合物的药物组合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。